Clinical trial NCT05895344: Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: an Open-label Randomized 1:1 Phase III Study
Official title: Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cavernous Sinus Meningioma
Proton-therapy
Photon Radiotherapy
Cognitive Impairment
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
Collaborators: name: National Cancer Institute, France
First posted: 2023-06-08
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multicenter prospective comparative phase 3 randomized 1:1 trial
Primary purpose: TREATMENT

Brief summary: Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi.

The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, cognitive impairment...). In 2012, Gondi reported that a dose given to 40% of the bilateral hippocampi greater than 7.3 Gy is associated with long-term impairment in list-learning delayed recall after FSRT for benign or low-grade adult brain tumors.

There is no published or recruiting prospective study evaluating the impact of proton-therapy or conventional irradiation on neurocognitive function for meningioma patients. Notably, long-term cognitive or ocular impact of these modern irradiation schemes remains poorly known. Yet, these patients had a long life-expectancy, and are at risk of developing long-term sequelae. Thus, according to its ballistic advantage, an improvement of patient functional outcomes and a reduction of neurocognitive long-term toxicity are expected if tissue sparing proton-therapy is used.

In this context, a randomized prospective study, evaluating long-term toxicity of these two irradiation modalities (Proton Therapy (PRT) and photon radiotherapy (XRT)) seems crucial to further assess proton-therapy indication for these patients.

Although literature reports excellent outcomes for intracranial meningioma patients treated by proton-therapy, none of the eight retrospective studies found in the literature used an accurate and full evaluation of long-term toxicity


Eligibility criteria: Inclusion Criteria:

* Cavernous sinus meningioma for which clinical target volume is larger than 3 centimeters
* Anterior skull base meningioma, invading by contiguity the cavernous sinus can be included
* Histologic proven Grade I meningioma
* Meningioma for which biopsy is not safely achievable and for which growing and imaging criteria are in favour of grade I meningioma can be included
* Age \>18 years and \<60 years
* Indication of irradiation validated by a pluridisciplinary meeting
* Adjuvant or exclusive irradiation is allowed.
* Use of conventional fractionation: 1.8Gy (RBE)/fraction
* Signed informed consent form
* WHO Performance status equal to 0 or 1
* Patient affiliated to the French social health insurance
* MoCA score ≥ cut-off of GRECOGVASC normative data (Roussel, 2016, cf annexe 1)
* Patient whose neuropsychological abilities allow to follow the requirements of the protocol

Exclusion Criteria:

* Patient with mutation in a known predisposition gene (NF-2, SMARCE-1...)
* Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease and other dementias, organic psychosis (other than dementia), schizophrenia, and neurodegenerative disease
* Radiosurgery, hypofractionated regimen
* Other localization than cavernous sinus
* Histologic proven Grade II or III meningioma
* Patient with unadjusted antiepileptic drug
* Contraindication to MRI
* Patient with a history of brain irradiation
* Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma)
* Pregnant/breastfeeding woman
* Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
* Participation in a therapeutic trial for less than 30 days
* Patient deprived of freedom or under guardianship

Primary outcomes:
measure: functional deterioration evaluated by individual neurocognitive test scores
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: Centre François Baclesse
city: Clamart
country: France
facility: Hopital d'Instruction des Armées PERCY
city: Grenoble
country: France
facility: CHU Grenoble-Alpes
city: Lyon
country: France
facility: Centre Léon Bérard
city: Lyon
country: France
facility: Hospices civils de Lyon
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Paris
country: France
facility: Hôpital Pitié Salpétrière
city: Paris
country: France
facility: Institut Curie
city: Saint-Cloud
country: France
facility: Institut Curie
city: Strasbourg
country: France
facility: Centre Paul Strauss
city: Toulouse
country: France
facility: IUCT
Study officials:
References: